CytomX Therapeutics (CTMX) EBT Margin (2014 - 2026)
CytomX Therapeutics (CTMX) posted EBT Margin of 177.32% for Q1 2026, up 95.56% on a QoQ basis from 3990.35% in Q4 2025, and down 22364.0% year-over-year from N/an in Q1 2025.
CytomX Therapeutics (CTMX) EBT Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics' EBT Margin history runs 13 years deep, the most recent figure standing at 177.32% for Q1 2026.
- Quarterly EBT Margin fell 22364.0% year-over-year to 177.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 165.74% (down 19409.0% YoY) and the FY2025 annual result came in at 22.48%, down 4572.0% from the prior year.
- EBT Margin was 177.32% for Q1 2026 at CytomX Therapeutics, up from 3990.35% in the prior quarter.
- Across five years, EBT Margin topped out at 49.72% in Q4 2024 and bottomed at 3990.35% in Q4 2025.
- A 5-year average of 303.63% and a median of 14.09% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin jumped 33968 bps — and 2025, when it plunged 404006 bps.
- CytomX Therapeutics' EBT Margin stood at 43.61% in 2022, then surged by 116 bps to 7.16% in 2023, then surged by 594 bps to 49.72% in 2024, then plunged by 8126 bps to 3990.35% in 2025, then jumped by 96 bps to 177.32% in 2026.
- Business Quant data shows CTMX's EBT Margin at 177.32% in Q1 2026, 3990.35% in Q4 2025, and 237.65% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -177.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.32% |
| Dec 31, 2025 | -3,990.35% |
| Sep 30, 2025 | -237.65% |
| Jun 30, 2025 | -0.49% |
| Mar 31, 2025 | 46.32% |
| Dec 31, 2024 | 49.72% |
| Sep 30, 2024 | 17.34% |
| Jun 30, 2024 | -25.81% |
| Mar 31, 2024 | 33.38% |
| Dec 31, 2023 | 7.16% |
| Sep 30, 2023 | 22.04% |
| Jun 30, 2023 | -4.40% |
| Mar 31, 2023 | -14.09% |
| Dec 31, 2022 | -43.61% |
| Sep 30, 2022 | -260.73% |
| Jun 30, 2022 | -229.49% |
| Mar 31, 2022 | -353.77% |
| Dec 31, 2021 | -312.82% |
| Sep 30, 2021 | -337.16% |
| Jun 30, 2021 | -303.99% |